Medtronic announced results of a study published in JAMA Network Open that demonstrates a reduction in health care utilization and cost for cancer pain patients using targeted drug delivery and conventional medical management vs. CMM alone.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe